Skip to main content

Psoriatic arthritis

Five Takeaways in PsA/SpA at RNL 2024

Feb 20, 2024

Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls. 

Read Article
Oral IL-23 Inhibitor Effective in Psoriasis The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). https://t.co/NRK8LnM5zp https://t.co/FnWEze976O
Dr. John Cush @RheumNow( View Tweet )
Feb 19, 2024
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/w2OO0t3PtR https://t.co/0oh5fDqVhJ
Dr. John Cush @RheumNow( View Tweet )
Feb 18, 2024
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf
Dr. John Cush @RheumNow( View Tweet )
Feb 16, 2024
Current PsA treatment options. A review with @RWCSmtg @JointMD #RWCS24 @RheumNow https://t.co/9I0TfyILvQ
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2024
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 15, 2024
Sex Disparities in PsA/SpA https://t.co/3pmFyo6Ztm https://t.co/zanPiI7GT5
Dr. John Cush @RheumNow( View Tweet )
Feb 15, 2024
Obesity increase risk of psoriasis Obesity increase risk of PsA in psoriasis pts RWCS24 https://t.co/Wt9h0QLbKH
Dr. John Cush @RheumNow( View Tweet )
Feb 14, 2024
Co-management of Psoriatic Disease It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. Co-management with dermatology optimises the care of this patient group. https://t.co/8xZ9ZBpa3O https://t.co/xMYLhxA1j1
Dr. John Cush @RheumNow( View Tweet )
Feb 14, 2024

Sex Disparities in PsA/SpA

Feb 13, 2024

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article

Co-management of Psoriatic Disease

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning

Read Article
Racial and Ethnic Determinants of Psoriatic Arthritis A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity. https://t.co/uJD5DWZEwM https://t.co/5dg0ubQzvL
Dr. John Cush @RheumNow( View Tweet )
Feb 10, 2024
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
Dr. John Cush @RheumNow( View Tweet )
Feb 10, 2024

Oral IL-23 Inhibitor Effective in Psoriasis

Feb 09, 2024

The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). 



This phase 2 dose-finding trial randomized 255 PSO patients, with moderate-to-

Read Article
Racial and Ethnic Determinants of Psoriatic Arthritis A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity. https://t.co/lHQxchTSyU https://t.co/AcXcpvuGI8
Dr. John Cush @RheumNow( View Tweet )
Feb 07, 2024

Racial and Ethnic Determinants of Psoriatic Arthritis

Feb 05, 2024

A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.

Read Article

Pre-Treatment Testing with Biologics Falls Short

Feb 01, 2024

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

Read Article
Enthesitis @lihi_eder @RheumNow #RNL2024 - NSAID - 1st line in mild/isolated - GC injxn but caution at Achilles - MTX cond rec by GRAPPA (SEAM PsA) - All bDMARD work vs PBO (TNFi, IL17, 12/23, 23, JAK, PDE4) - none superior - IL17 v ADA: higher resol for IXE v ADA, but mixed data https://t.co/20KnQo4kpq
Eric Dein @ericdeinmd( View Tweet )
Jan 28, 2024
Advanced therapies in enthesitis. Don't believe the spin, they all work, no clear evidence that any agent is better than others. @lihi_eder @RheumNow #RNL2024 https://t.co/FwLMUmmClB
Richard Conway @RichardPAConway( View Tweet )
Jan 28, 2024
#RNL2024 @RheumNow @lihi_eder on enthesitis - ~1/3 PsA, SpA - Enthesitis precedes onset of PsA in PsO, high u/s score ass. w/ RFs (BMI, nail dyst) - Exam: tenderness (non-specific), as swelling uncommon. U/s helpful, but non-specif - Marker of severity, higher risk of damage

Eric Dein @ericdeinmd( View Tweet )

Jan 28, 2024
Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients. #RNL2024 @RheumNow https://t.co/bPLR7zpNe2
Dr. Rachel Tate @uptoTate( View Tweet )
Jan 28, 2024
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕. Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Unique and selective allosteric mechanism of deucravacitinib. Eric Ruderman #RNL2024 @RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Diagnostic delay in SpA 2.3 years longer delay in diagnosis in women with PsA. @lihi_eder #RNL2024 @RheumNow https://t.co/d9ao8vvpa5
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex @KDAO2011( View Tweet )
Jan 27, 2024